Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 9, 2012

IDT Buys 1st Base Custom Oligo Business to Serve Clients in Asia

  • Integrated DNA Technologies (IDT) acquired 1st Base’s oligonucleotide business in Singapore. IDT is renaming the business 1st Base Custom Oligos (FBCO). The 1st Base brand will also be retained for small-scale DNA oligos manufactured at the plant.

    IDT says the acquisition will provide it with its first synthesis facility in Asia, for providing locally manufactured custom oligonucleotides and services  to researchers in Singapore and throughout the region. FBCO will offer DNA and RNA synthesis, oligonucleotide modification, qPCR assays and probes, RNAi synthesis, and gene synthesis products and services.

    “We’re just getting started in Asia, and we have a lot to learn about the needs of the researchers working here,” comments Joseph Walder, Ph.D., IDT founder and CEO. "But with FBCO up and running, and with the support of our new colleagues from 1st Base, we aim to build on IDT’s success in North America and in Europe.”

    IDT provides custom DNA and RNA oligonucleotides and genes to academic, government, and commercial clinets in the biotech, clinical diagnostics, and pharmaceuticals sectors. The firm claims to synthesize and ship an average of 36,000 oligos per day. The firm already operates manufacturing facilities on Iowa, California, and Belgium.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »